Opus Genetics
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
Something off on this page? Send us feedback.
Profile
Develops mutation-specific AAV gene therapies for inherited retinal diseases while retaining partnered phentolamine eye-drop economics and APX3330 development. Revenue comes from the Viatris collaboration, while the gene-therapy candidates remain investigational.
Develops a portfolio of mutation-specific AAV gene-therapy programs for inherited retinal diseases, including OPGx-LCA5 and OPGx-BEST1 in human testing, alongside preclinical and pre-IND candidates. The portfolio targets underlying genetic causes of severe retinal disorders and is developed through academic licenses, clinical sites, contract organizations, and partner support.
Retains small-molecule ophthalmology assets from Ocuphire. Viatris commercializes RYZUMVI for reversal of pharmacologically induced mydriasis and funds development activities under its license; phentolamine is also being studied for presbyopia and night-driving impairment, while APX3330 is a post-midstage diabetic-retinopathy asset. All reported revenue comes from the Viatris collaboration, and every gene-therapy candidate remains investigational.
Company facts
Key statistics
Year to date +75.0% · Average volume (30d) 867.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Reiterate | Outperform | $10 | $9 |
| Jul 29, 2026 | Cowen & Co. | Initiate | Buy | ||
| Jun 23, 2026 | RBC Capital | Initiate | Outperform | $10 | |
| Jun 17, 2026 | H.C. Wainwright | Target | $8 | ||
| May 21, 2026 | Leerink Partners | Target | $10 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.16 | −$0.14 | +10.6% | $2.6M | $755.0K | −71.3% | −1.59% |
| May 21, 2026Q1 FY26 | −$0.16 | −$0.19 | −18.8% | $3.1M | $3.9M | +22.9% | −0.70% |
| May 12, 2026Q1 FY26 | −$0.16 | −$0.75 | −368.7% | $2.9M | $2.2M | −26.3% | −2.90% |
| Nov 12, 2025Q3 FY25 | −$0.14 | −$0.12 | +14.3% | $3.1M | $3.1M | +0.2% | −3.65% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $2.9M | $3.1M | $3.9M | $2.2M | $755.0K | |
| Gross profit | $4.4M | −$3.1M | $3.1M | $3.9M | $2.1M | $755.0K | |
| Operating income | −$9.9M | −$8.9M | −$8.3M | −$11.5M | −$14.4M | −$16.5M | |
| Net income | −$8.2M | −$7.4M | −$17.5M | −$16.5M | −$65.5M | −$8.1M | |
| Diluted EPS | −$0.24 | −$0.12 | −$0.25 | −$0.19 | −$0.75 | −$0.08 | |
| Gross margin | 100.0% | -109.0% | 100.0% | 100.0% | 99.4% | 100.0% | |
| Operating margin | -227.2% | -309.0% | -269.9% | -296.3% | -665.9% | -2,182.8% |
Fiscal years (4-quarter sums)FY21 $589.0K · FY22 $39.9M · FY23 $19.0M · FY24 $11.0M · FY25 $14.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $88.8M · Total debt $34.9M · Total assets $93.0M · Shareholders' equity −$13.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 82.57M · Float 34.98M · 42.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 8.83M | 9.99% | 13G | May 15, 2026 |
| Caligan Partners LP | 6.08M | 8.50% | 13G | May 15, 2026 |
| Adage Capital Management, L.P. | 6.03M | 8.47% | 13G | May 13, 2026 |
| Balyasny Asset Management L.P. | 5.11M | 7.18% | 13G | May 15, 2026 |
| Nantahala Capital Management, LLC | 4.84M | 6.51% | 13G | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 23, 2026 | Robert E. Gagnon | officer: Chief Financial Officer | −7,783 | $2.95 |
| Jul 23, 2026 | George Magrath | director, officer: Chief Executive Officer | −9,475 | $2.95 |
| Jul 23, 2026 | Joseph K. Schachle | officer: Chief Operating Officer | −4,644 | $2.94 |
| Jul 23, 2026 | Benjamin R. Yerxa | director, officer: President | −7,429 | $2.97 |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund | director, other: See Remarks | −1,700,000 | $4.35 |
Peers
- AbbVie
Marketed presbyopia-drop rival through VUITY.
- LENZ
Commercial presbyopia-drop rival through VIZZ.
- Regeneron
Established injectable alternative in diabetic retinopathy.
- Ocugen
Late-stage modifier gene therapy rival in inherited retinal disease.
- MeiraGTx
LCA gene-therapy developer with a partnered AAV-AIPL1 program.
